PPB05
Crete, Greece
May 9th - 12th, 2005
 
   

Program structure

View the final program.


Monday
May 9
Tuesday
May 10
Wednesday
May 11
Thursday
May 12
Friday
May 13
Day of arrival 08.30-12.00
Session 1;
Product Developments and New Technologies
08.30-12.00
Session 3; Manufacturing
08.30-12.00
Session 5; Pathogen Safety Issues
 Day of departure
   Lunch  Buffet lunch  Buffet lunch  

16.00-19.00
Registration

19.00 Welcome
19.15 Keynote
Lecture

13.00-16.00 Excursion to Spinalonga 

17.00-17.30
Focus Lecture 1

17.30-20.30
Session 2; Recombinant Plasma Proteins

 Free time


16.00-17.00 Poster Session; Authors to be available
17.00-17.30
Focus Lecture 2 17.30-20.30
Session 4; Hyperimmune and Intraveneous IgG

 Free time


15.00-18.30
Session 6;
Applications of Plasma Products and Clinical Developments

 
 20.00- Welcome Reception      19.30 -
Crete Night Dinner
 

Keynote Lecture
"Plasma Protein Products: how far have we come, how far do we go?"
Dr. Graham D. Sher,
Chief Executive Officer, Canadian Blood Services, Ottawa, ONT, Canada

Focus Lecture 1
Comparability Protocols, FDA´s Perspective and Experience
Dr. Andrew Chang
Div Hematology, FDA, Rockville, MD, USA

Focus Lecture 2
TSE’s and Medicinal Products. Regulatory aspects in the EU.
Dr. Sol Ruiz
Spanish Medicines Agency, Madrid, Spain


The program of PPB05 will be structured around the following sessions.
Main Topic Chairman Affiliation
Product Developments and New Technologies Jan Over Sanquin Blood Supply Foundation, The Netherlands
Recombinant Plasma Proteins Joe Bertolini CSL Ltd, Australia
Manufacturing Johan Vandersande Baxter Healthcare Corp., USA
Pathogen Safety Issues Bernard Horowitz New York, USA
Hyperimmune and Intraveneous IgG Wytold Lebing Bayer Corp., USA
Applications of Plasma Products and Clinical Developments Hubert Heinrichs ZLB Behring GmbH, Germany

 
   

Return to Program Structure 

 Session 1; Product Developments and New Technologies
Chairman; Jan Over, Sanquin Blood Supply Foundation, The Netherlands

The Product Development and New Technologies session will primarily focus on leads for developing new plasma proteins for clinical application, and on the development of new protein purification technologies and other production technologies applicable in the area of downstream processing.
Novel applications of already existing production technologies, as well as innovative improvements of existing protein products may also qualify for presentation. The same holds for techniques which can be used for characterising protein products.

 Session 3; Manufacturing
Chairman; Johan Vandersande, Baxter Healthcare Corp., USA

With today's pressures on margins in the plasma business, the Manufacturing Session should primarily focus on Cost. Therefore topics should preferably be related to cost reduction such as: yield improvement, supplies and labor cost reduction through automation initiatives and efficiency improvement as well as inventory reduction by cycle time improvement.

 Session 4; Hyperimmune and Intraveneous IgG
Chairman; Wytold Lebing, Bayer Corp., USA

This section will explore new uses for both Hyperimmune and Polyimmune IgG's. Papers on clinical experience with new indications for IgG's as well as novel and improved dosage forms will be encouraged. This section will also explore new manufacturing procedures. With special attention to methodologies which improve product safety and recovery.

 Session 5; Pathogen Safety Issues
Chairman; Bernard Horowitz, Horowitz Consulting, New Yourk, USA

Questions concerning the safety of purified blood derivatives continue despite their amassing an admirable safety record over the past 15 years. In addition to frequently explored topics - emerging threats, new methods of viral inactivation or removal, and the validity of viral samples used in spiking studies - the Safety Session of PPB2005 invites presentations that address the potential threat from vCJD sparked by its recent putative transmissions by red cell concentrates in the UK. Specifically, abstracts that address estimates of risk, assays applicable to blood screening, methods of removal including the development of specialized affinity resins, validation of high titered materials used in spiking studies, and cleaning protocols are encouraged